Neta Goldschmidt
Overview
Explore the profile of Neta Goldschmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
1853
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Topp M, Matasar M, Allan J, Ansell S, Barnes J, Arnason J, et al.
Blood
. 2025 Jan;
PMID: 39786390
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) progressing after chimeric antigen receptor T-cell therapy (CAR T) have dismal outcomes. The prespecified post-CAR T expansion cohort of the ELM-1...
2.
Kedmi M, Ribakovsy E, Benjamini O, Schiby G, Barshack I, Raskin S, et al.
Hematol Oncol
. 2024 Nov;
42(6):e70001.
PMID: 39572395
Therapy for relapsed or refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (aB-NHL) post autologous stem cell transplantation (ASCT) or in elderly patients can be challenging. In this single-center, single-arm, phase II...
3.
Furstenau M, Kater A, Robrecht S, von Tresckow J, Zhang C, Gregor M, et al.
Lancet Oncol
. 2024 May;
25(6):744-759.
PMID: 38821083
Background: In the primary analysis report of the GAIA/CLL13 trial, we found that venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib improved undetectable measurable residual disease (MRD) rates and progression-free survival compared with chemoimmunotherapy in...
4.
Noerenberg D, Briest F, Hennch C, Yoshida K, Hablesreiter R, Takeuchi Y, et al.
J Clin Oncol
. 2023 Dec;
42(4):452-466.
PMID: 38055913
Purpose: Primary mediastinal large B-cell lymphoma (PMBCL) is a rare aggressive lymphoma predominantly affecting young female patients. Large-scale genomic investigations and genetic markers for risk stratification are lacking. Patients And...
5.
Karavani G, Vedder K, Gutman-Ido E, Gruda Sussman R, Goldschmidt N, Mordechai-Daniel T, et al.
Hum Reprod
. 2023 Jul;
38(9):1705-1713.
PMID: 37414543
Study Question: Does chemotherapy exposure affect IVM potential of immature oocytes retrieved from the ovarian cortex following ovarian tissue cryopreservation (OTC) for fertility preservation? Summary Answer: The IVM potential of...
6.
Bairey O, Lebel E, Buxbaum C, Porges T, Taliansky A, Gurion R, et al.
Hematol Oncol
. 2023 Jul;
41(5):838-847.
PMID: 37403752
Primary central nervous system lymphoma (PCNSL) is a rare disease with an incidence of 0.4/per 100,000 person-years. As there is a limited number of prospective randomized trials in PCNSL, large...
7.
Berger T, Shochat T, Aumann S, Nachmias B, Goldschmidt N, Horesh N, et al.
Ann Hematol
. 2023 Jun;
102(8):2127-2136.
PMID: 37335322
The GALLIUM study showed a progression-free survival advantage of 7% in favor of obinutuzumab vs. rituximab-based immunochemotherapies as first-line therapy in follicular lymphoma (FL) patients. Yet, the toxicity appears to...
8.
Furstenau M, Thus Y, Robrecht S, Mellink C, van der Kevie-Kersemaekers A, Dubois J, et al.
Blood
. 2023 May;
142(5):446-459.
PMID: 37172204
Complex karyotypes have been associated with inferior outcomes in chronic lymphocytic leukemia (CLL) treated with chemoimmunotherapy (CIT), whereas their prognostic impact in the context of venetoclax-based treatments is still debated....
9.
Aumann S, Tsubary U, Nachmias B, Yehuda D, Lavie D, Goldschmidt N, et al.
Eur J Haematol
. 2023 Apr;
111(1):135-145.
PMID: 37096337
Background: Studies addressing coronavirus disease 2019 (COVID-19) in patients with hematological malignancies have reported mortality rates of up to 40%; however, included predominantly hospitalized patients. Methods: During the first year...
10.
Kabiri D, Gavra H, Haran T, Goldschmidt N, Elazary R, Mei-Zahav M
Eur J Obstet Gynecol Reprod Biol
. 2023 Feb;
283:158-159.
PMID: 36801085
No abstract available.